Madam Speaker Hon Lydia Johnson KZN Premier, Honourable Senzo Mchunu Honourable Members of the KZN Legislature Madam Speaker; allow me to start by expressing our sympathy to the Ngcobo family at UMzinyathi in Inanda for their loss of a beloved ... South African Government, 1 month ago
MEC Sibongiseni Dhlomo - Statement On Shortage of Essential Medicines [press release] - Individual.com, 1 month ago
Romark Laboratories and Lupin Pharmaceuticals Respond to Recent Cryptosporidium (Crypto) Outbreak in Johnson County, Kan.
_ TAMPA, FL and BALTIMORE, MD -- (Marketwired) -- 08/21/15 -- Two pharmaceutical companies with expertise in infectious diseases today responded to an outbreak of cryptosporidiosis (Crypto), an illness spread through swimming pools, water parks and ...Sys-Con Media, 1 week ago
Well known industrial property veteran Tim Johnson has joined Chancerygate to help its ambitious industrial development push. Johnson is joining Chancerygate to expand the scope of the company's development programme. Chancerygate managing director ...CoStar Uk, 1 month ago
By a News Reporter-Staff News Editor at Journal of Engineering -- Johnson & Johnson Consumer Companies, Inc. ( Skillman, NJ ) has been issued patent number 9084810, according to news reporting originating out of Alexandria, Virginia , by ...4 Traders, 1 month ago
by Abbie Chapman Johnson, Keith J. Nagle, Sarah M. Tremble, Marilyn J. Cipolla Eclampsia, clinically defined as unexplained seizure in a woman with preeclampsia, is a life threatening complication unique to the pregnant state. However, a ...Plosone.org, 1 month ago
| Author: Daniel Puddicombe The London Assembly is calling for the mayor of London, Boris Johnson, to introduce a £2.50 levy on all diesel vehicles entering central London from next year. The proposal comes after the ...What Van, 1 month ago London Assembly recommends tougher stance on diesels in new report Business Car, 1 month ago West End 'green corridor' could ease London's air pollution problem Environmental Data Interactive Exchange, 1 month ago
Johnson & Johnson - Phase 2B Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis
Release date- 09072015 - Spring House, Pa., Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe ...Pharmacy Choice, 1 month ago Phase 2B Findings Published In The NEJM Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis Drugs.com, 1 month ago Janssen Research & Development Release: Phase 2b Findings Published In Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis BioSpace, 1 month ago
Johnson & Johnson : Janssen's IMBRUVICA®?(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia
- Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA®▼ (ibrutinib) capsules as a treatment option for adult patients with Waldenström's macroglobulinemia (WM) who have received at ...4 Traders, 1 month ago IMBRUVICA®▼(ibrutinib) de Janssen reçoit une autre approbation donnée par la Commission européenne pour le traitement de la macroglobulinémie de Waldenström PR Newswire, 1 month ago Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European Commission Approval for the Treatment of.. ADVFN India, 1 month ago Janssen's IMBRUVICA®?(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia Noodls, 1 month ago
More from: , SOA World Magazine...and 2 other sources
PFE: flat ABT: flat MRK: flat AMGN: +0.06% Health-care shares were higher in pre-market trade Thursday with Johnson & Johnson ( JNJ ) and Amgen ( AMGN ) edging higher. In health-care stocks news, Mylan ( MYL ) Thursday said it has launched in ...Nasdaq, 1 month ago
Source: Amgen via Flickr. Whether you realize it or not, biotech blue-chip stock Amgen ( NASDAQ:AMGN ) has had a stellar year. You may not see that reflected in its share price considering the magnitude of the recent stock market correction, but ...Motley Fool, 1 day ago
on your WebpageAdd Widget >Get your members hooked!